POM logo

POMDOCTOR LTD - A

POMNASDAQ
πŸ† #4647 by market capUS Equity
$1.70β–² $0.09 (+5.28%)
Market closed Β· at close
πŸ””
Track POM
Get earnings, price moves & breaking news on Telegram
Track
24hβ–² 5.3%
7dβ–² 2.1%
14dβ–² 6.6%
30dβ–² 43.6%
ytdβ–Ό 90.5%
1yβ–Ό 99.4%
🏦Market Cap
$15M
Small Cap
πŸ“ˆRevenue Growth (YoY)
16.7%
Healthy
πŸ“ŠGross Margin
11.7%
Thin
πŸ’΅FCF Margin
-37.3%
Thin
βš–οΈP/S Ratio
0.3x
Cheap
Otter Score
β€”
Insufficient data

Trading Snapshot

Day Range
$1.54 – $1.70
52-Week Range
$0.43 – $102.42
Volume (shares)
13,870
Avg Volume (shares)
β€”
Shares Outstanding
8.6M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$400M
Last Q Revenue
$27M
P/E Ratio
-0.2
P/S Ratio
0.3x
EPS (TTM)
$-37.37
Dividend Yield
0.00%
Dilution (1yr)
+106.8%
POM logo

POMDOCTOR LTD - A

POM
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$400Mβ–² +16.7% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
13.1%β–Ό βˆ’6.1% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
βˆ’$116Mβ–² +351.2% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
βˆ’$149Mβ–² +824.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
4.4Mβ–² +106.8% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
βˆ’$445Mβ–Ό βˆ’$12M YoY
StockOtter Β· stockotter.space

About POMDOCTOR LTD - A

Pomdoctor Limited, operating through its various divisions, runs an e-commerce platform for the direct sale of pharmaceutical products to consumers. The company is actively developing an online healthcare services platform specifically designed for managing long-term illnesses within the Chinese market. Its primary emphasis is on chronic disease care and pharmaceutical provision, facilitating a digital portal that connects patients with medical professionals and essential medications. Pomdoctor's operations largely encompass both a virtual hospital model and a comprehensive pharmaceutical supply chain, thus linking individual users, pharmacies, distributors, medical experts, and other healthcare stakeholders. This enterprise was established in 2010 and is headquartered in Guangzhou, China.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)

Insufficient data for all five components.

πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Insufficient data
β€”/100
Analyst data unavailable.

Latest News & Updates

PRNewsWireΒ·11d ago

POMDOCTOR LIMITED Highlights Real-World Data as a Strategic Foundation for AI-Enabled Healthcare Solutions

Company emphasizes the expanding applications of real-world data in medical research, clinical decision-making, healthcare payment and personalized treatment GUANGZHOU, China, Nov. 11, 2026 /PRNewswire/ -- POMDOCTOR LIMI

PRNewsWireΒ·16d ago

POMDOCTOR LIMITED Regains Compliance with Nasdaq Bid Price Requirement

GUANGZHOU, China, Nov. 6, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare c

PRNewsWireΒ·18d ago

POMDOCTOR LIMITED Advances Strategic Evolution from Traffic Monetization to Value-Based Healthcare Payment

Building a Four-Tier Revenue Structure Across B2C Services, AI-Enabled Chronic Disease Management, B2B Healthcare Services, and Pharmaceutical RWS/RWD GUANGZHOU, China, Nov. 4, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Po

PRNewsWireΒ·20d ago

POMDOCTOR LIMITED Announces Receipt of Nasdaq Notifications Regarding Continued Listing Requirements

GUANGZHOU, China, Nov. 2, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (Nasdaq: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions and predictive healthcare c

PRNewsWireΒ·Oct 19

POMDOCTOR LIMITED Announces the Termination of Its ADR Program and Trade Class A Ordinary Shares on Nasdaq

GUANGZHOU, China, Oct. 19, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solution

PRNewsWireΒ·Oct 12

POMDOCTOR LIMITED Highlights the Shift from Reactive Treatment to Predictive Healthcare

GUANGZHOU, China, Oct. 12, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing artificial intelligence ("AI")-enabled healthcare solution